EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Yeast-Based Vaccine Platforms: Applications and Key Insights from the COVID-19 Era

Piyush Baindara iD, Roy Dinata iD, Ravinder Kumar iD

Biomolecules · 2026

DOI: 10.3390/biom16010116 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, 2026. Verfasst von Piyush Baindara und 2 weiteren Autor:innen. Beteiligte Einrichtung: Animal Science Research Center, Division of Animal Sciences, University of Missouri, Columbia, MO 65211, USA. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19, Saccharomyces cerevisiae. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID-19 pandemic accelerated vaccine innovation but also exposed weaknesses in global access and manufacturing. Yeast-based platforms, particularly Saccharomyces cerevisiae and Pichia pastoris, also known as Komagataella phaffii, offer a practical complement to vector systems. These eukaryotic microorganisms combine safety, scalability, and cost-effectiveness with the ability to express complex antigens and assemble virus-like particles. Building on the success of the recombinant hepatitis B vaccine, recent advances in glycoengineering, CRISPR-based host optimization, and surface display technologies have expanded the utility of yeast-based platforms for the rapid development of vaccines. Yeast-derived SARS-CoV-2 receptor-binding domain (RBD) subunit vaccines, such as Corbevax and Abdala (CIGB-66), demonstrate that affordable, immunogenic, and thermostable products are feasible at scale. Emerging innovations in glycan humanization, thermostable formulations, and oral or mucosal delivery highlight the potential of yeast-based vaccines for decentralized manufacturing and equitable pandemic preparedness. This review summarizes recent technical and clinical progress in yeast-based vaccine research, positioning these platforms as accessible and adaptable tools for future outbreak responses and global immunization strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesCOVID-19Saccharomyces cerevisiaeHumansSARS-CoV-2Protein Subunit VaccinesPandemicsVaccine DevelopmentVaccines, SyntheticVaccines, SubunitSaccharomycetales

Stichwörter der Autor:innen

COVID-19SARS-CoV-2pandemic preparednessyeast surface displayyeast-based vaccine

Substanzen

COVID-19 VaccinesProtein Subunit VaccinesVaccines, SyntheticVaccines, Subunit

Autor:innen und Institutionen

  • Animal Science Research Center, Division of Animal Sciences, University of Missouri, Columbia, MO 65211, USA.
  • National Swine Testing Center, University of Missouri, Columbia, MO 65211, USA.
  • Department of Clinical Pharmacy & Translational Science, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, USA.

ORCID-Profile: Piyush Baindara, Roy Dinata, Ravinder Kumar

Zitieren

APA

Baindara, P., Dinata, R., & Kumar, R. (2026). Yeast-Based Vaccine Platforms: Applications and Key Insights from the COVID-19 Era. Biomolecules. https://doi.org/10.3390/biom16010116

Vancouver

Baindara P, Dinata R, Kumar R. Yeast-Based Vaccine Platforms: Applications and Key Insights from the COVID-19 Era. Biomolecules. 2026. doi:10.3390/biom16010116

BibTeX
@article{Baindara2026,
  author = {Baindara, Piyush and Dinata, Roy and Kumar, Ravinder},
  title = {Yeast-Based Vaccine Platforms: Applications and Key Insights from the COVID-19 Era},
  journal = {Biomolecules},
  year = {2026},
  doi = {10.3390/biom16010116}
}
Kostenlos starten →